- ￥1320
- BHcell（博辉生物）
- H-C715
- 2026年01月06日
企业认证
万千商家帮你免费找货
0 人在求购买到急需产品
- 详细信息
- 文献和实验
- 技术资料
- 规格：
T25
vero E6、vero E6、vero E6细胞、vero E6细胞、vero E6非洲绿猴肾细胞
Cell line name Vero C1008
Synonyms VERO C1008; VeroC1008; VEROC1008; VERO C 1008; VERO C1008 (E6); Vero 76 clone E6; Vero 76 clone E-6; Vero E-6; Vero E6; VERO E6; Vero-E6; VeroE6
Accession CVCL_0574
Resource Identification Initiative To cite this cell line use: Vero C1008 (RRID:CVCL_0574)
Comments Group: Non-human primate cell line.
Group: Vaccine production cell line.
Virology: Susceptible to infection by many viruses. Supports the growth of slowly replicating viruses (ATCC=CRL-1586).
Virology: Susceptible to infection by SARS coronavirus (SARS-CoV). Produces a lytic infection (PubMed=15731278; PubMed=16494729).
Virology: Susceptible to infection by SARS coronavirus 2 (SARS-CoV-2) (COVID-19) (PubMed=32020029; PubMed=32511316; PubMed=33389257; PubMed=34339474).
Doubling time: 22 hours (ATCC=CRL-1586).
Derived from site: In situ; Kidney, epithelium; UBERON=UBERON_0004819.
Cell type: Epithelial cell of kidney; CL=CL_0002518.
Species of origin Chlorocebus sabaeus (Green monkey) (Cercopithecus sabaeus) (NCBI Taxonomy: 60711)
Hierarchy Parent: CVCL_0603 (Vero 76)
Children:
CVCL_D7CA (Abeomics Vero ACE2) CVCL_D7CB (Abeomics Vero GFP) CVCL_JX48 (sVero p66)
CVCL_E1F0 (Ubigene Vero E6 ATG7 KO) CVCL_E1F1 (Ubigene Vero E6 GSDME KO) CVCL_E1F2 (Ubigene Vero E6 PIK3C3 KO)
CVCL_E1F4 (Ubigene Vero E6 STAT1 KO) CVCL_E1F6 (Ubigene Vero E6 ZDHHC20 KO) CVCL_A7UJ (Vero E6-high ACE2)
CVCL_XD71 (Vero E6-S) CVCL_C7NK (Vero E6-TMPRSS2-T2A-ACE2) CVCL_YZ66 (Vero E6/NPC1-KO cl.19)
CVCL_C4RQ (VeroE6-Pgp-KO) CVCL_YQ49 (VeroE6/TMPRSS2)
Sex of cell Female
Age at sampling Adult
Category Spontaneously immortalized cell line
Publications
CLPUB00328
Earley E.M., Johnson K.M.
The lineage of Vero, Vero 76 and its clone C1008 in the United States.
(In book chapter) Vero cells: origin, properties and biomedical applications; Simizu B., Terasima T. (eds.); pp.26-29; Department of Microbiology, School of Medicine, Chiba University; Chiba; Japan (1988)
PubMed=15731278; DOI=10.1128/JVI.79.6.3846-3850.2005; PMCID=PMC1075706
Mossel E.C., Huang C., Narayanan K., Makino S., Tesh R.B., Peters C.J.
Exogenous ACE2 expression allows refractory cell lines to supportplication.
J. Virol. 79:3846-3850(2005)
PubMed=16494729; DOI=10.3201/eid1201.050496; PMCID=PMC3291385
Kaye M., Druce J., Tran T., Kostecki R., Chibo D., Morris J., Catton M., Birch C.
SARS-associated coronavirus replication in cell lines.
Emerg. Infect. Dis. 12:128-133(2006)
PubMed=19016439; DOI=10.1002/9780471729259.mca04es11; PMCID=PMC2657228
Ammerman N.C., Beier-Sexton M., Azad A.F.
Growth and maintenance of Vero cell lines.
Curr. Protoc. Microbiol. 11:A.4E.1-A.4E.7(2008)
PubMed=32020029; DOI=10.1038/s41422-020-0282-0; PMCID=PMC7054408
Wang M.-L., Cao R.-Y., Zhang L.-K., Yang X.-L., Liu J., Xu M.-Y., Shi Z.-L., Hu Z.-H., Zhong W., Xiao G.-F.
Remdesivir and chloroquine effectively inhibit the recently emerged novel coronavirus (2019-nCoV) in vitro.
Cell Res. 30:269-271(2020)
PubMed=32511316; DOI=10.1101/2020.03.02.972935; PMCID=PMC7239045
Harcourt J.L., Tamin A., Lu X.-Y., Kamili S., Kumar-Sakthivel S., Murray J., Queen K., Tao Y., Paden C.R., Zhang J., Li Y., Uehara A., Wang H.-B., Goldsmith C., Bullock H.A., Wang L.-J., Whitaker B., Lynch B., Gautam R., Schindewolf C., Lokugamage K.G., Scharton D., Plante J.A., Mirchandani D., Widen S.G., Narayanan K., Makino S., Ksiazek T.G., Plante K.S., Weaver S.C., Lindstrom S., Tong S.-X., Menachery V.D., Thornburg N.J.
Isolation and characterization of SARS-CoV-2 from the first US COVID-19 patient.
bioRxiv 2020:972935-972935(2020)
PubMed=33389257; DOI=10.1007/s10096-020-04106-0; PMCID=PMC7778494
Wurtz N., Penant G., Jardot P., Duclos N., La Scola B.
Culture of SARS-CoV-2 in a panel of laboratory cell lines, permissivity, and differences in growth profile.
Eur. J. Clin. Microbiol. Infect. Dis. 40:477-484(2021)
PubMed=34339474; DOI=10.1371/journal.pone.0255622; PMCID=PMC8328321
Pommerenke C., Rand U., Uphoff C.C., Nagel S., Zaborski M., Hauer V., Kaufmann M., Meyer C., Denkmann S.A., Riese P., Eschke K., Kim Y., Safranko Z.M., Kurolt I.-C., Markotic A., Cicin-Sain L., Steenpass L.
Identification of cell lines CL-14, CL-40 and CAL-51 as suitable models for SARS-CoV-2 infection studies.
PLoS ONE 16:E0255622-E0255622(2021)
风险提示：丁香通仅作为第三方平台，为商家信息发布提供平台空间。用户咨询产品时请注意保护个人信息及财产安全，合理判断，谨慎选购商品，商家和用户对交易行为负责。对于医疗器械类产品，请先查证核实企业经营资质和医疗器械产品注册证情况。
文献和实验*发表【中文论文】请标注：由博辉生物科技（广州）有限公司提供； *发表【英文论文】请标注：From Bohui Biological Technology (Guangzhou) Co., Ltd.
vero（非洲绿猴肾cell):贴壁细胞，以25ml小方瓶为例，培养液用的是MEM。 MEM的配制：10%小牛血清，1%双抗，3%谷氨酰胺，1~1.5%NaHCO3. 传代方法： 1、倒掉培养液，如果细胞脏的话可用PBS洗两次，否则不用。 2.、胰酶0.25%2ml消化1~3分钟，容易消化. 3、倒掉胰酶，加MEM9~12ml,将贴壁细胞摇至悬浮，并用吸管吹匀，一传三或一传四。 4、置37度，5%CO2孵箱。
考虑的问题之一。 Vero细胞的正式名称为“非洲绿猴肾细胞”，是传代细胞的一种。所谓传代细胞可简单的理解为，在体外可以连续传代的细胞系，理论上具有无限传代的寿命。传代细胞系可以通过以下方法衍生而来，（1）正常细胞群的连续传代，繁衍成一个新的具有无限寿命的细胞群，例如非洲绿猴肾细胞的传代细胞系Vero细胞；（2）人或动物肿瘤细胞的原代细胞的系列培养，例如Hela细胞、Namalva细胞等；（3）携带致癌基因的病毒，将致癌基因转化给正常细胞，成为肿瘤细胞，例如EB病毒转化的B淋巴细胞；（4）骨髓
edwardellen 求助！！！ 本人菜鸟，最近开始接触凋亡相关信号，在HepG-2中做实验，有一点很困惑，HepG-2中的p53是野生型的还是突变型的？还是两者都存在？查了一些资料，有些文章之间表达的意思模凌两可。困惑啊！ 哪位好心的达人能给我一个确定的答案呢？ 另外，是否有做p53相关的牛人能告诉我P53在哪些实验用肿瘤细胞系中是野生型的，在哪些是突变型的？ 谢谢！谢谢！谢谢！ doctormy
技术资料